Even if bone marrow morphology and cytogenetics are the backbone of diagnosing and monitoring a BCR-ABL-negative MPN, no current guidelines have yet to be published on the clinical algorithm in which a PMF with basophilia should be managed. This evidence concerns the gene ABL1 and myeloproliferative neoplasm.